TITLE

UCB SELLS OTC DELSYM TO ADAMS RESPIRATORY THERAPEUTICS

PUB. DATE
July 2006
SOURCE
Worldwide Biotech;Jul2006, Vol. 18 Issue 7, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the decision of UCB SA to sell Delsym, an over-the-counter drug, to Adams Respiratory Therapeutics Inc. Terms of the agreement; Use of Delsym as a cough medication in the U.S.; Background on the operations of UCB.
ACCESSION #
21352197

 

Related Articles

  • Sales speak volumes for silent switch.  // Drug Store News;4/5/2004, Vol. 26 Issue 5, p17 

    Reports on the sales performance of Mucinex, an over-the-counter (OTC) cough expectorant brand of Adams Respiratory Therapeutics, for the period ending December 28, 2003. Approval from the U.S. Food and Drug Administration for Adams Respiratory Therapeutics to market an OTC cough expectorant;...

  • Adams coughs up cash for Delsym line.  // Drug Store News;6/26/2006, Vol. 28 Issue 8, p14 

    The article reports on the acquisition of Adams Respiratory Therapeutics of the Delsym cough suppressant brand from biopharmaceutical company UCB in Chester, New Jersey. The move will increase the market share of Adams in pediatric cough and cold aisles, and will secure the company's patented...

  • REPORTERS Notebook.  // Drug Store News;4/23/2007, Vol. 29 Issue 6, p50 

    The article reports developments in the pharmaceutical industry in the U.S. Nine new over-the-counter products it intends to launch in early fiscal 2008 was launched by Adams Respiratory Therapeutics. Bayer Nutritional Science line, a new line of nutritional supplements was introduced by Bayer...

  • Were Mucinex's Sales Goosed by FDA Lobbying? Edwards, Jim // Brandweek;4/9/2007, Vol. 48 Issue 15, p7 

    The article examines whether the success of Adams Respiratory Therapeutics' Mucinex is attributed to a popular advertising campaign or the company's ties with federal regulators. The article explains that Mucinex has become one of the leaders in the over-the-counter drug industry, which the...

  • Delayed season, children's niche impact cough/cold market. Scalise, Annette // Drug Store News;1/15/2001, Vol. 23 Issue 1, p31 

    Deals with the factors that affect cough and cold market of over the counter drugs. Delay of the season; Withdrawal of phenylpropanolamine-containing products and flu vaccine shortages; Why suppliers and retailers are looking at the market segment of children.

  • REPORTER'S NOTEBOOK.  // Drug Store News;3/6/2006, Vol. 28 Issue 3, p45 

    The article reports on developments related to the pharmaceutical industry in the U.S. Perrigo Co. has received final approval to begin marketing over-the-counter nicotine polarcrilex lozenges. Adams Respiratory Therapeutics announced its plans to enter the pediatric market. Quigley Corp....

  • What's the best over-the-counter cough remedy? HOUSTON, TOM // Men's Health;Nov2013, Vol. 28 Issue 9, p26 

    The article provides an answer to a question related to the most effective over-the-counter drug for cough.

  • ABOUT UCB.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p6 

    The article provides information on UCB, a biopharmaceutical firm based in Brussels, Belgium, with over 8,000 employees in 40 countries, and is listed on the Euronext Brussels under the UCB symbol.

  • OTC.  // Drug Topics;12/11/2006, Vol. 150 Issue 23, p89 

    The article evaluates several products including Children's Mucinex MiniMelts cough granules from Adams Respiratory Therapeutics, Immune Fizz vitamins from Zipfizz Corp., and InfiAid dietary supplement from Infinity Health Sciences and offers information on its features.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics